Below are some of the key findings from this hydronephrosis drugs industry analysis report
The global hydronephrosis drugs market is expected to grow at a CAGR of more than 9% during the forecast
Hydronephrosis therapies industry growth is expected to accelerate massively over the next five years driven by the growing prevalence of kidney diseases that result in a higher incidence of hydronephrosis. Hydronephrosis is caused by kidney related diseases such as UTIs, CKDs, and kidney stones. According to the CDC, around 30 million people in the US are affected by CKD, which is likely to augment the growth of the global hydronephrosis treatment market. Furthermore, the increasing prevalence of ESRD, another kidney related disorder, will drive the demand for treatment of hydronephrosis across the period of forecast. Technavio's hydronephrosis therapies industry analysis reveals promising markets around the world.
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.
Americas will be the largest driver of growth for the global hydronephrosis drugs market
Almost 41% of the incremental growth of the global hydronephrosis therapies market will be driven by the Americas during the forecast period, while EMEA and APAC are predicted to make sizeable contributions to the market growth. The Americas also held the largest share of around 22% in the global hydronephrosis therapies market, followed by EMEA and APAC respectively. However, APAC is forecasted to generate the fastest rate of growth in the global hydronephrosis therapies market over the next five years while the Americas will register a slightly higher CAGR than EMEA during the same period.
Allergan, F. Hoffmann-La Roche, and Novartis are among the leading vendors in the hydronephrosis drugs market
The global hydronephrosis therapies market is slated to become extremely fragmented with the presence of several vendors who offer products such as antibiotic therapy and other therapies for treatment hydronephrosis. Hydronephrosis is characterized by dilation or stretching of the inside of the kidney and therapeutics such as analgesics and kidney stone drugs are used for hydronephrosis treatment. Many international and regional vendors are vying for their share of the global hydronephrosis therapies market, and players must differentiate themselves to gain vital traction over their peers.
This report offers a complete analysis of several companies, including:
F. Hoffmann-La Roche
Teva Pharmaceutical Industries
We can help! Our analysts can customize this report to meet your requirements. Get in touch